Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz® would be the first ...

The FDA has accepted a sNDA for Ameluz topical gel, used in combination with the RhodoLED red-light lamp series, for superficial basal cell carcinoma treatment.

The FDA accepted the supplemental new drug application (sNDA) for aminolevulinic acid hydrochloride 10% topical gel (Ameluz) as part of photodynamic therapy (PDT) for superficial basal cell carcinoma ...

Skin cancer is the most common type of cancer in the United States with 5.4 million new cases of the disease reported every year. TODAY contributor and New Beauty editor-at-large Sarah Eggenberger ...

Basal cell carcinoma (BCC) represents the most prevalent form of skin cancer, with research efforts increasingly focused on elucidating its molecular underpinnings and improving therapeutic strategies ...

Basal cell carcinoma has low immunogenicity. Tumor cells express Foxc1 protein (red), which suppresses HLA class I (green) in the tumor cells. Compromised antigen presentation ranks among the top ...

A new study led by researchers at the Johns Hopkins Kimmel Cancer Center found that patients with advanced basal cell carcinoma (BCC) may benefit from receiving immunotherapy earlier in the course of ...

Prescription Drug User Fee Act (PDUFA) target action date set for September 28, 2026If approved, Ameluz would be the first and only PDT photosensitizer indicated for the treatment of superficial Basal ...